Amarantus appoints board member
This article was originally published in Scrip
Executive Summary
Amarantus BioScience, which develops treatments and diagnostics for neurodegeneration and apoptosis diseases, has named Mark Benedyk to its board of directors. Dr Benedyk has severed as a corporate advisor to Sunnyvale, California-based Amarantus since 2011. Dr Benedyk is currently a managing partner at business and corporate development consultancy, Rila Partners. He serves on the strategic advisory board of KemPharm, is a director at the Center for Drug Research and Development Ventures and is a member of the translational medicine advisory board of the CNS Regenerative Medicine Foundation. With the addition of Dr Benedyk, Amarantus has four board members.